The Coalition for Epidemic Preparedness Innovations (CEPI) Partners With Bharat Biotech, and Others to Make a 'Variant-Proof' COVID Vaccine

It will fund the researchers to conduct activities including immunogen design, preclinical studies, and a Phase 1 clinical trial. In this, modified immunogens will be produced in a scalable process with high purity and yield at a low cost.

Related Keywords

Australia ,India ,Sydney ,New South Wales ,Bharat ,James Triccas ,Krishna Ella ,Mariaj Wurm ,Sydney Institute For Infectious Diseases ,University Of Sydney ,Managing Director ,Professor James Triccas ,Sydney Institute ,Infectious Diseases ,Bharat Biotech ,Vaccine ,Covid 19 ,Mcepi ,Health ,